Compare · BIO vs NAUT
BIO vs NAUT
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Nautilus Biotechnology Inc. (NAUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and NAUT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $9.75B, about 35.5x NAUT ($274.9M).
- Over the past year, BIO is up 13.6% and NAUT is up 110.9% - NAUT leads by 97.3 points.
- NAUT has been more active in the news (3 items in the past 4 weeks vs 1 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 9 for NAUT).
- Company
- Bio-Rad Laboratories Inc.
- Nautilus Biotechnology Inc.
- Price
- $353.60-3.03%
- $2.06-4.19%
- Market cap
- $9.75B
- $274.9M
- 1M return
- -7.58%
- +112.15%
- 1Y return
- +13.58%
- +110.89%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2020
- News (4w)
- 1
- 3
- Recent ratings
- 12
- 9
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest BIO
- Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
Latest NAUT
- Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Roth Capital initiated coverage on Nautilus Biotechnology with a new price target
- SEC Form EFFECT filed by Nautilus Biotechnology Inc.
- SEC Form 424B5 filed by Nautilus Biotechnology Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by Nautilus Biotechnology Inc.
- Leerink Partners initiated coverage on Nautilus Biotechnology with a new price target
- Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.